Gastrointestinal Cancer

Rocio Garcia-Carbonero, MD, discusses the rationale for the phase 2b VIRAGE trial in patients with metastatic pancreatic cancer.

Daniel King, MD, PhD, discusses the need to develop less-toxic regimens for advanced gastrointestinal cancers.

This is a final overall survival analysis on the phase 3 CARES-310 study (NCT03764293), a randomized, open-label, international phase 3 trial comparing camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC).

Shubham Pant, MD, MBBS, discusses the utility of zanidatamab in patients with previously treated HER2+ biliary tract cancer.

Pamela L. Kunz, MD, discusses a subanalysis of the NETTER-2 study investigating frontline lutetium Lu 177 dotatate in advanced, well-differentiated GEP-NETs.

Suneel Kamath, MD, discusses the rationale for conducting an investigation into the tumor microbiome differences between early- and average-onset PDAC.

Next generation capecitabine led to positive preliminary efficacy results in patients with stage III or IV gastrointestinal tract cancer.

Frontline toripalimab plus bevacizumab improved progression-free survival and overall survival vs sorafenib in patients with advanced hepatocellular carcinoma.

The strength of mKRAS-specific T-cell responses produced by ELI-002 7P correlated with tumor biomarker responses in pancreatic and colorectal cancer.

Michael Cecchini, MD, discusses interim data on the use of CM24 with nivolumab and NALIRIFOX in advanced/metastatic pancreatic ductal adenocarcinoma.

Suneel Kamath, MD, discusses tumor microbiome differences between early-onset and average-onset pancreatic adenocarcinoma.

China’s National Medical Products Administration has accepted the biologics license application for zanidatamab in second-line HER2+ biliary tract cancer.

Olverembatinib showed antitumor activity in patients with TKI-resistant, SDH-deficient GISTs and paraganglioma.

Jennifer R. Eads, MD, discusses neoadjuvant pCR rates with the addition of nivolumab to neoadjuvant chemoradiation in esophageal/GEJ cancer.

Olivia Aranha, MD, PhD, discusses data supporting the use of HIPEC for patients with peritoneal carcinomatosis in gastrointestinal malignancies.

Michael Iglesia, MD, PhD, discusses the potential role of disease etiology in frontline HCC treatment decision-making.

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for Avzivi, a monoclonal antibody referencing bevacizumab.

OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Arndt Vogel, MD, on the final overall survival data for camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma.

Rivoceranib plus camrelizumab maintained a survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.

Zanidatamab continued to show confirmed responses, disease control, and prolonged overall survival in pretreated HER2+ biliary tract cancer.

Perioperative chemotherapy with FLOT improved OS vs neoadjuvant chemoradiation with CROSS in resectable esophageal cancer.

The FDA accepted the resubmission of the BLA for first-line zolbetuximab in CLDN18.2-positive, HER2-negative, advanced gastric or GEJ adenocarcinoma.

Pitavastatin, an FDA-approved statin, may inhibit pathways that contribute to IL-33 production, which has been shown to contribute to cancer development.

Daniel M. Halperin, MD, discusses the FDA approval of lutetium Lu 177 dotatate for pediatric patients with SSTR-positive GEP-NETs.